SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Rowland Charles A Jr

(Last) (First) (Middle)
C/O ORCHARD THERAPEUTICS PLC
108 CANNON STREET

(Street)
LONDON X0 EC4N 6EU

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2020
3. Issuer Name and Ticker or Trading Symbol
Orchard Therapeutics plc [ ORTX ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1) 12,294 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) (2) 06/11/2028 Ordinary Shares(1) 80,030 4.74 D
Stock Option (Right to Buy) (3) 06/25/2029 Ordinary Shares(1) 35,000 13.2 D
Explanation of Responses:
1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
2. 26,411 shares subject to this option vested on June 1, 2019 and the remaining shares vest in equal monthly installments over the two years thereafter.
3. All of the shares subject to this option vest upon the earlier to occur of June 26, 2020 or the date of the 2020 Annual General Meeting of the Company.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Charles A. Rowland, Jr. 01/02/2020
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of John Ilett, Mark
Rothera, and Frank
Thomas, signing singly, and with full power of substitution, the undersigned's
true and
lawful attorney-in-fact to:

    (1)    execute for and on behalf of the undersigned, in the undersigned's
capacity
as officer and/or director of Orchard Therapeutics plc (the "Company"), from
time to time
the following U.S. Securities and Exchange Commission ("SEC") forms: (i) Form
ID, including
any attached documents (such as Update Passphrase Authentication), to effect the
assignment
of codes to the undersigned to be used in the transmission of information to the
SEC using
the EDGAR System; (ii) Form 3, Initial Statement of Beneficial Ownership of
Securities,
including any attached documents; (iii) Form 4, Statement of Changes in
Beneficial Ownership
of Securities, including any attached documents; (iv) Form 5, Annual Statement
of Beneficial
Ownership of Securities in accordance with Section 16(a) of the Securities
Exchange Act of
1934, as amended, and the rules thereunder, including any attached documents;
(v) Schedule
13D and (vi) amendments of each thereof, in accordance with the Securities
Exchange Act of
1934, as amended, and
 the rules thereunder, including any attached documents;

    (2)    do and perform any and all acts for and on behalf of the undersigned
which
may be necessary or desirable to complete and execute any such Form 3, 4 or 5,
Schedule 13D
or any amendment(s) thereto, and timely file such form(s) with the SEC and any
securities
exchange, national association or similar authority; and

    (3)    take any other action of any type whatsoever in connection with the
foregoing
which, in the opinion of such attorney-in-fact, may be of benefit to, in the
best interest of,
or legally required by, the undersigned, it being understood that the documents
executed by
such attorney-in-fact on behalf of the undersigned pursuant to this Power of
Attorney shall
be in such form and shall contain such terms and conditions as such
attorney-in-fact may approve
in such attorney-in-fact's discretion.

    The undersigned hereby grants to each such attorney-in-fact, acting singly,
full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary or
proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all
intents and purposes as the undersigned might or could do if personally present,
with full power
of substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or
such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to
be done by virtue
of this power of attorney and the rights and powers herein granted.  The
undersigned acknowledges
that the foregoing attorneys-in-fact, in serving in such capacity at the request
of the undersigned,
are not assuming, nor is the Company assuming, any of the undersigned's
responsibilities to comply
with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as
amended.  The
undersigned hereby agrees to indemnify the attorneys-in-fact and the Company
from and against
any demand, damage, loss, cost or expense arising from any false or misleading
information provided
by the undersigned to the attorneys-in-fact.

    This Power of Attorney shall be governed by, and construed in accordance
with, the laws of
the state of Delaware. This Power of Attorney shall remain in full force and
effect until the
undersigned is no longer required to file such forms with respect to the
undersigned's holdings of
and transactions in securities issued by the Company, unless earlier revoked by
the undersigned in
a signed writing delivered to the foregoing attorneys-in-fact.  This Power of
Attorney supersedes
any prior power of attorney in connection with the undersigned's capacity as an
officer and/or
director of the Company.  This Power of Attorney shall expire as to any
individual attorney-in-fact
if such attorney-in-fact ceases to be an officer of, or legal counsel to, the
Company.

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed
as of January 2, 2020.

                                         /s/ Charles Rowland
                                         ----------------------
                                         Charles Rowland